{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:54:25Z","timestamp":1793382865853,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bcp.2023.115584","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T21:10:39Z","timestamp":1683234639000},"page":"115584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pharmacological options in the treatment of osteogenesis imperfecta: A comprehensive review of clinical and potential alternatives"],"prefix":"10.1016","volume":"213","author":[{"given":"Javier","family":"Mu\u00f1oz-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Giurgea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Amselem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"L\u00e9zot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"William Vargas-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-018-0021-z","article-title":"The art of building bone: Emerging role of chondrocyte-to-osteoblast transdifferentiation in endochondral ossification","volume":"6","author":"Aghajanian","year":"2018","journal-title":"Bone Research"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0015","first-page":"105","article-title":"Alendronate treatment in children with osteogenesis imperfecta","volume":"45","author":"Akcay","year":"2008","journal-title":"Indian Pediatrics"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000351374","article-title":"Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age","volume":"79","author":"Alcausin","year":"2013","journal-title":"Hormone Research in Paediatrics"},{"key":"10.1016\/j.bcp.2023.115584_b0025","series-title":"Basic and Applied Bone Biology","first-page":"75","article-title":"Bone modeling and remodeling","author":"Allen","year":"2013"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/JPEM.2008.21.1.63","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta: Results of treatment and follow-up after discontinuation","volume":"21","author":"Andiran","year":"2008","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","article-title":"Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis","volume":"129","author":"Antoniazzi","year":"1996","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00128072-200002060-00005","article-title":"Osteogenesis imperfecta: Practical treatment guidelines","volume":"2","author":"Antoniazzi","year":"2000","journal-title":"Paediatric Drugs"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0045","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0050","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1177\/0022034514567334","article-title":"Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta","volume":"94","author":"Apolin\u00e1rio","year":"2015","journal-title":"Journal of Dental Research"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1259\/dmfr.20150400","article-title":"Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment","volume":"45","author":"Apolin\u00e1rio","year":"2016","journal-title":"Dentomaxillofacial Radiology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0060","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/adc.2006.096552","article-title":"Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta","volume":"92","author":"\u00c5str\u00f6m","year":"2007","journal-title":"Archives of Disease in Childhood"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbm4.10118","article-title":"A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta","volume":"3","author":"Bains","year":"2019","journal-title":"JBMR Plus"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0070","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","author":"Baroncelli","year":"2014","journal-title":"Hormone Research in Paediatrics"},{"issue":"9","key":"10.1016\/j.bcp.2023.115584_b0075","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: A clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0080","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0022-3476(97)70074-X","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"131","author":"Bembi","year":"1997","journal-title":"Journal of Pediatrics"},{"issue":"9902","key":"10.1016\/j.bcp.2023.115584_b0085","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: A randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.bcp.2023.115584_b0090","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1517\/14656566.2015.1064897","article-title":"Odanacatib for the treatment of osteoporosis","volume":"16","author":"Boggild","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.bcp.2023.115584_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/biom11101493","article-title":"Osteogenesis imperfecta: Current and prospective therapies","volume":"11","author":"Botor","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","article-title":"Risedronate in adults with osteogenesis imperfecta type I: Increased bone mineral density and decreased bone turnover, but high fracture rate persists","volume":"23","author":"Bradbury","year":"2012","journal-title":"Osteoporosis International"},{"issue":"June","key":"10.1016\/j.bcp.2023.115584_b0105","first-page":"3","article-title":"Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives","volume":"146","author":"Bregou","year":"2016","journal-title":"Swiss Medical Weekly"},{"issue":"9\u201310","key":"10.1016\/j.bcp.2023.115584_b0110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","article-title":"Mevalonate pathway: A review of clinical and therapeutical implications","volume":"40","author":"Buhaescu","year":"2007","journal-title":"Clinical Biochemistry"},{"key":"10.1016\/j.bcp.2023.115584_b0115","series-title":"Basic and Applied Bone Biology","first-page":"3","article-title":"Bone morphology and organization","author":"Burr","year":"2013"},{"key":"10.1016\/j.bcp.2023.115584_b0120","first-page":"1","article-title":"Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis","volume":"12","author":"Chandra","year":"2017","journal-title":"The FASEB Journal"},{"issue":"10","key":"10.1016\/j.bcp.2023.115584_b0125","article-title":"Hereditary Metabolic Bone Diseases: A Review of Pathogenesis","volume":"13","author":"Charoenngam","year":"2022","journal-title":"Diagnosis and Management. Genes"},{"issue":"11","key":"10.1016\/j.bcp.2023.115584_b0130","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: A 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jbspin.2013.04.014","article-title":"Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38","volume":"80","author":"Clavel","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bcp.2023.115584_b0145","doi-asserted-by":"crossref","unstructured":"De Mar\u00e9, A., D\u2019haese, P. C., & Verhulst, A. (2020). The role of sclerostin in bone and ectopic calcification. International Journal of Molecular Sciences, 21(9). https:\/\/doi.org\/10.3390\/ijms21093199.","DOI":"10.3390\/ijms21093199"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11926-009-0023-3","article-title":"Clinical update on teriparatide","volume":"11","author":"Deal","year":"2009","journal-title":"Current Rheumatology Reports"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","article-title":"Denosumab: A Review in Postmenopausal Osteoporosis","volume":"35","author":"Deeks","year":"2018","journal-title":"Drugs and Aging"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0160","article-title":"Current overview of osteogenesis imperfecta","volume":"57","author":"Deguchi","year":"2021","journal-title":"Medicina (Lithuania)"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0165","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skeletal Radiology"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0170","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1471-4892(02)00218-7","article-title":"New uses of bisphosphonates: Osteogenesis imperfecta","volume":"2","author":"Devogelaer","year":"2002","journal-title":"Current Opinion in Pharmacology"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0175","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","article-title":"Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta","volume":"35","author":"Dimeglio","year":"2004","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1210\/er.2015-1114","article-title":"Cathepsin K inhibitors for osteoporosis: Biology, potential clinical utility, and lessons learned","volume":"38","author":"Drake","year":"2017","journal-title":"Endocrine Reviews"},{"issue":"10","key":"10.1016\/j.bcp.2023.115584_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"2016","author":"Dwan","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0195","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bone.2011.02.011","article-title":"Bisphosphonates for postmenopausal osteoporosis","volume":"49","author":"Eastell","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2023.115584_b0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-3-642-54490-3_20","article-title":"Bortezomib","volume":"201","author":"Einsele","year":"2014","journal-title":"Recent Results Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0210","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00774-014-0609-3","article-title":"Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis","volume":"33","author":"Feng","year":"2015","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0215","first-page":"11","article-title":"Osteoclasts : New Insights","volume":"1","author":"Feng","year":"2013","journal-title":"Nature Publishing Group"},{"key":"10.1016\/j.bcp.2023.115584_b0220","doi-asserted-by":"crossref","unstructured":"Ferrer Ca\u00f1abate J., Tovar I., M. P. (2002). Osteoprotegerina y Sistema RANKL\/RANK: \u00bfel Futuro del Metabolismo \u00d3seo? Anales de Medicina Interna, 19(3), 385\u2013388. https:\/\/doi.org\/10.4321\/S0212-71992002000800001.","DOI":"10.4321\/S0212-71992002000800001"},{"key":"10.1016\/j.bcp.2023.115584_b0225","unstructured":"Friedman, P. A. (2018). Agents that affect bone mineral homeostasis. In McGraw-Hill Education (Ed.), Basic & Clinical Pharmacology (Thirteen E, pp. 772\u2013792)."},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0235","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0240","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/TCRM.S35788","article-title":"Clinical development of neridronate: Potential for new applications","volume":"9","author":"Gatti","year":"2013","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0245","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcified Tissue International"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1590\/S0004-27302006000400019","article-title":"Anabolic skeletal therapy for osteoporosis","volume":"50","author":"Girotra","year":"2006","journal-title":"Arquivos Brasileiros de Endocrinologia e Metabologia"},{"issue":"14","key":"10.1016\/j.bcp.2023.115584_b0255","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate therapy in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"The New England Journal o f Medicine"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0260","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.bone.2010.02.018","article-title":"Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes","volume":"46","author":"Gooi","year":"2010","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11914-020-00594-3","article-title":"Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta","volume":"18","author":"G\u00f6therstr\u00f6m","year":"2020","journal-title":"Current Osteoporosis Reports"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0270","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nature Medicine"},{"issue":"12","key":"10.1016\/j.bcp.2023.115584_b0275","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: Mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"International Journal of Clinical Practice"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0280","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/13543776.2019.1608180","article-title":"A patent review of bisphosphonates in treating bone disease","volume":"29","author":"Holstein","year":"2019","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1359-6101(00)00030-7","article-title":"Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands","volume":"12","author":"Horowitz","year":"2001","journal-title":"Cytokine and Growth Factor Reviews"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0290","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfecta - A first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"Journal of Musculoskeletal Neuronal Interactions"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years\u2019 experience with denosumab for children with Osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1197-z","article-title":"Individualized treatment with denosumab in children with osteogenesis imperfecta - Follow up of a trial cohort","volume":"14","author":"Hoyer-Kuhn","year":"2019","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0305","first-page":"mvv112","article-title":"The role of osteoclast differentiation and function in skeletal homeostasis","volume":"159","author":"Ikeda","year":"2015","journal-title":"Journal of Biochemistry"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0310","first-page":"29","article-title":"The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta","volume":"4","author":"Ipach","year":"2012","journal-title":"Orthopedic Reviews"},{"issue":"March","key":"10.1016\/j.bcp.2023.115584_b0315","first-page":"1","article-title":"Drug Discovery of DKK1 Inhibitors","volume":"13","author":"Jiang","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0320","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11914-017-0357-0","article-title":"Exploiting the WNT Signaling Pathway for Clinical Purposes","volume":"15","author":"Johnson","year":"2017","journal-title":"Current Osteoporosis Reports"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0325","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types","volume":"43","author":"Jovanovic","year":"2022","journal-title":"Endocrine Reviews"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ecc.12740","article-title":"The biology of normal bone remodelling","volume":"26","author":"Katsimbri","year":"2017","journal-title":"European Journal of Cancer Care"},{"issue":"20","key":"10.1016\/j.bcp.2023.115584_b0335","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0340","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0004563218759371","article-title":"The bone remodelling cycle","volume":"55","author":"Kenkre","year":"2018","journal-title":"Annals of Clinical Biochemistry"},{"key":"10.1016\/j.bcp.2023.115584_b0350","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4068\/cmj.2016.52.1.12","article-title":"Signaling Pathways in Osteoclast Differentiation","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med J"},{"issue":"12","key":"10.1016\/j.bcp.2023.115584_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm7120479","article-title":"Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis\u2014Case series","volume":"7","author":"Kobayashi","year":"2018","journal-title":"Journal of Clinical Medicine"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0360","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2023.115584_b0365","doi-asserted-by":"crossref","unstructured":"Li, L. jiao, Zheng, W. bin, Zhao, D. chen, Yu, W., Wang, O., Jiang, Y., Xia, W. bo, & Li, M. (2019). Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta. Bone, 127(1), 164\u2013171. https:\/\/doi.org\/10.1016\/j.bone.2019.06.011.","DOI":"10.1016\/j.bone.2019.06.011"},{"issue":"19","key":"10.1016\/j.bcp.2023.115584_b0370","first-page":"3049","article-title":"Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta","volume":"124","author":"Li","year":"2011","journal-title":"Chinese Medical Journal"},{"issue":"February","key":"10.1016\/j.bcp.2023.115584_b0375","first-page":"1","article-title":"The Role of Semaphorin 3A in Bone Remodeling","volume":"11","author":"Li","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.bcp.2023.115584_b0380","doi-asserted-by":"crossref","unstructured":"Lindahl, K., Kindmark, A., Rubin, C. J., Malmgren, B., Grigelioniene, G., S\u00f6derh\u00e4ll, S., Ljunggren, & \u00c5str\u00f6m, E. (2016). Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Bone, 87, 11\u201318. https:\/\/doi.org\/10.1016\/j.bone.2016.02.015.","DOI":"10.1016\/j.bone.2016.02.015"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0385","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nm.4076","article-title":"LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption","volume":"22","author":"Luo","year":"2016","journal-title":"Nature Medicine"},{"issue":"12","key":"10.1016\/j.bcp.2023.115584_b0390","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4158\/EP161322.OR","article-title":"Effects of Long-Term Alendronate Treatment on a Large Sample of Pediatric Patients With Osteogenesis Imperfecta","volume":"22","author":"Lv","year":"2016","journal-title":"Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0395","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/JOE-11-0048","article-title":"The skeleton: A multi-functional complex organ. The growth plate chondrocyte and endochondral ossification","volume":"211","author":"Mackie","year":"2011","journal-title":"Journal of Endocrinology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0400","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.rhu.0000208490.22492.09","article-title":"Alendronate treatment in osteogenesis imperfecta","volume":"12","author":"Madenci","year":"2006","journal-title":"Journal of Clinical Rheumatology"},{"issue":"7","key":"10.1016\/j.bcp.2023.115584_b0405","first-page":"2","article-title":"Total absence of the alpha2(I) chain of collagen type I causes a rare form of Ehlers-Danlos syndrome with hypermobility and propensity to cardiac valvular problems","volume":"43","author":"Malfait","year":"2006","journal-title":"Journal of Medical Genetics"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0410","first-page":"142","article-title":"Bone remodeling: a social network of cells","volume":"34","author":"Marie","year":"2012","journal-title":"Medicographia"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0415","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","article-title":"Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: High predictive value of the carboxyterminal propeptide of type I procollagen","volume":"18","author":"Marini","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0420","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40265-019-01072-6","article-title":"Romosozumab: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0425","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.c.31532","article-title":"Pharmacological and biological therapeutic strategies for osteogenesis imperfecta","volume":"172","author":"Marom","year":"2016","journal-title":"American Journal of Medical Genetics, Part C: Seminars in Medical Genetics"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0430","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Osteogenesis imperfecta: An update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"European Journal of Endocrinology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0435","first-page":"139","article-title":"Osteogenesis Imperfecta: An Update on Clinical Features and Therapies","volume":"183","author":"Maron","year":"2020","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.bcp.2023.115584_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042018820904016","article-title":"New perspectives on the treatment of skeletal dysplasia","volume":"11","author":"Marzin","year":"2020","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0445","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00774-020-01153-7","article-title":"RANKL as a target for the treatment of osteoporosis","volume":"39","author":"Matsumoto","year":"2021","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0450","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.abb.2008.03.027","article-title":"Osteoclast-osteoblast communication","volume":"473","author":"Matsuo","year":"2008","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"May","key":"10.1016\/j.bcp.2023.115584_b0455","article-title":"History of risedronate","volume":"137","author":"McClung","year":"2020","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bcp.2023.115584_b0460","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S2213-8587(19)30346-8","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study","volume":"7","author":"McClung","year":"2019","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"10.1016\/j.bcp.2023.115584_b0465","doi-asserted-by":"crossref","unstructured":"Miller, S. A., St. Onge, E. L., & Whalen, K. L. (2021). Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis. Journal of Pharmacy Technology, 37(1), 45\u201352. https:\/\/doi.org\/10.1177\/8755122520967632.","DOI":"10.1177\/8755122520967632"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0470","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1023\/A:1011024200280","article-title":"Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration","volume":"18","author":"Mitchell","year":"2001","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.bcp.2023.115584_b0475","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.matbio.2018.03.010","article-title":"Osteogenesis imperfecta and therapeutics","volume":"71\u201372","author":"Morello","year":"2018","journal-title":"Matrix Biology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0480","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2004.03.008","article-title":"Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta","volume":"35","author":"Munns","year":"2004","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bcp.2023.115584_b0485","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/JBMR.050213","article-title":"Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome","volume":"20","author":"Munns","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0490","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.acthis.2009.10.003","article-title":"Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology","volume":"113","author":"Narducci","year":"2011","journal-title":"Acta Histochemica"},{"key":"10.1016\/j.bcp.2023.115584_b0495","series-title":"PubChem Subgraph Fingerprint","author":"National Center for Biotechnology Information","year":"2009"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0500","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jbmr.3312","article-title":"Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy","volume":"33","author":"Nicol","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.bcp.2023.115584_b0505","series-title":"Goodman & Gilman\u2019s: The pharmacological basis of therapeutics","first-page":"887","article-title":"Agents affecting mineral ion homeostasis and bone turnover","author":"Nolin","year":"2017"},{"key":"10.1016\/j.bcp.2023.115584_b0510","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky","year":"2017","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0515","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00418-018-1636-2","article-title":"Recent advances in osteoclast biology","volume":"149","author":"Ono","year":"2018","journal-title":"Histochemistry and Cell Biology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0520","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0525","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporosis International"},{"issue":"December 2019","key":"10.1016\/j.bcp.2023.115584_b0530","article-title":"Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective","volume":"134","author":"Papapoulos","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2023.115584_b0535","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.msec.2017.05.042","article-title":"Strontium and strontium ranelate: Historical review of some of their functions","volume":"78","author":"Pilmane","year":"2017","journal-title":"Materials Science and Engineering C"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0540","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.bcp.2023.115584_b0545","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2016.02.003","article-title":"Osteocytes: The master cells in bone remodelling","volume":"28","author":"Prideaux","year":"2016","journal-title":"Current Opinion in Pharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0550","first-page":"65","article-title":"Strontium ranelate in post-menopausal osteoporosis","volume":"62","author":"Przedlacki","year":"2011","journal-title":"Endokrynologia Polska"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0555","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0149-2918(04)90128-2","article-title":"Teriparatide: A review","volume":"26","author":"Quattrocchi","year":"2004","journal-title":"Clinical Therapeutics"},{"issue":"9773","key":"10.1016\/j.bcp.2023.115584_b0560","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: Now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"The Lancet"},{"issue":"February","key":"10.1016\/j.bcp.2023.115584_b0565","first-page":"1","article-title":"Management of Osteogenesis Imperfecta","volume":"10","author":"Ralston","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0570","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/07853890510007386","article-title":"Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long?","volume":"37","author":"Rauch","year":"2005","journal-title":"Annals of Medicine"},{"issue":"7","key":"10.1016\/j.bcp.2023.115584_b0575","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: A randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0580","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","article-title":"Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation","volume":"91","author":"Rauch","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0585","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy","volume":"18","author":"Rauch","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0590","first-page":"809","article-title":"Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice & Research. Clinical","volume":"28","author":"Reginster","year":"2014","journal-title":"Endocrinology & Metabolism"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0595","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.semcdb.2008.08.002","article-title":"Anti-resorptive therapies for osteoporosis","volume":"19","author":"Reid","year":"2008","journal-title":"Seminars in Cell and Developmental Biology"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0600","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bone.2010.09.002","article-title":"Bisphosphonates in Paget\u2019s disease","volume":"49","author":"Reid","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2023.115584_b0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reuma.2011.03.003","article-title":"Mecanismos de interacci\u00f3n osteoblasto-osteoclasto","volume":"7","author":"Riancho","year":"2011","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"issue":"April","key":"10.1016\/j.bcp.2023.115584_b0610","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2019.04.021","article-title":"Mendelian bone fragility disorders","volume":"126","author":"Robinson","year":"2019","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0615","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bcp.2023.115584_b0620","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/13543784.7.9.1521","article-title":"Expert Opinion on Investigational Drugs Olpadronate : a new amino-bisphosphonate for the treatment of medical osteopathies","volume":"7","author":"Rold\u00e1n","year":"1998","journal-title":"Exp. Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0625","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/MOP.0000000000000813","article-title":"Osteogenesis imperfecta - advancements in genetics and treatment","volume":"31","author":"Rossi","year":"2020","journal-title":"Curr Opin Pediatr."},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0630","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: From Bench to Bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0635","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: The first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2023.115584_b0640","doi-asserted-by":"crossref","unstructured":"Sakkers, R., Kok, D., Engelbert, R., A., V. D., Jansen, M., Pruijs, H., Verbout, A., Schweitzer, D., & Uiterwaal, C. (2004). Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study. Lancet, 363(9419), 1427\u20131431. http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L38586718%0Ahttp:\/\/dx.doi.org\/10.1016\/S0140-6736(04)16101-1.","DOI":"10.1016\/S0140-6736(04)16101-1"},{"key":"10.1016\/j.bcp.2023.115584_b0645","doi-asserted-by":"crossref","unstructured":"Sanvoranart, T., Supokawej, A., Kheolamai, P., U-Pratya, Y., Klincumhom, N., Manochantr, S., Wattanapanitch, M., & Issaragrisil, S. (2014). Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues. Biochemical and Biophysical Research Communications, 447(4), 580\u2013585. https:\/\/doi.org\/10.1016\/j.bbrc.2014.04.044.","DOI":"10.1016\/j.bbrc.2014.04.044"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0650","first-page":"805","article-title":"Odanacatib: An emerging novel treatment alternative for postmenopausal osteoporosis","volume":"11","author":"Schultz","year":"2015","journal-title":"Women\u2019s Health"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0655","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000331128","article-title":"Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta","volume":"76","author":"Semler","year":"2011","journal-title":"Hormone Research in Paediatrics"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0660","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta Type VI","volume":"12","author":"Semler","year":"2012","journal-title":"Journal of Musculoskeletal Neuronal Interactions"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0665","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40272-019-00330-0","article-title":"Current and Emerging Therapeutic Options for the Management of Rare Skeletal Diseases","volume":"21","author":"Semler","year":"2019","journal-title":"Pediatric Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0670","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/adc.2007.125468","article-title":"Two doses of pamidronate in infants with osteogenesis imperfecta","volume":"93","author":"Senthilnathan","year":"2008","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1016\/j.bcp.2023.115584_b0675","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","article-title":"Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: A systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"American Journal of Therapeutics"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0680","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pbiomolbio.2016.05.012","article-title":"The role of R-spondins and their receptors in bone metabolism","volume":"122","author":"Shi","year":"2016","journal-title":"Progress in Biophysics and Molecular Biology"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0685","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00774-016-0806-3","article-title":"Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis","volume":"35","author":"Shiraki","year":"2017","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0690","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"Journal of Medical Genetics"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0695","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semcdb.2008.07.016","article-title":"Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption","volume":"19","author":"Sims","year":"2008","journal-title":"Seminars in Cell and Developmental Biology"},{"issue":"August 2013","key":"10.1016\/j.bcp.2023.115584_b0700","first-page":"481","article-title":"Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit","volume":"3","author":"Sims","year":"2014","journal-title":"BoneKEy Reports"},{"issue":"12","key":"10.1016\/j.bcp.2023.115584_b0705","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-8587(19)30348-1","article-title":"Odanacatib: the best osteoporosis treatment we never had?","volume":"7","author":"Statham","year":"2019","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0710","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s00774-013-0494-1","article-title":"Strontium ranelate: In search for the mechanism of action","volume":"31","author":"Stepan","year":"2013","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0715","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bcp.13869","article-title":"Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis","volume":"85","author":"Stone","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1016\/j.bcp.2023.115584_b0720","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1210\/clinem\/dgac366","article-title":"Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children","volume":"107","author":"Sun","year":"2022","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0725","first-page":"1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib","volume":"58","author":"Tan","year":"2018","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.bcp.2023.115584_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107666","article-title":"TGF\u03b2-Directed Therapeutics: 2020","volume":"217","author":"Teicher","year":"2021","journal-title":"Pharmacology and Therapeutics"},{"issue":"5","key":"10.1016\/j.bcp.2023.115584_b0735","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-\u03baB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0740","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: Involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine and Growth Factor Reviews"},{"key":"10.1016\/j.bcp.2023.115584_b0745","first-page":"187","article-title":"Handbook of Experimental Pharmacology: Preface","volume":"195","author":"Thieme","year":"2010","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.bcp.2023.115584_b0750","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.metabol.2017.06.001","article-title":"Osteogenesis imperfecta \u2013 A clinical update","volume":"80","author":"Tournis","year":"2018","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0755","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"Journal of Musculoskeletal Neuronal Interactions"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0760","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","article-title":"Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report","volume":"6","author":"Uehara","year":"2022","journal-title":"Modern Rheumatology Case Reports"},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0765","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jped.2014.05.003","article-title":"What is new in genetics and osteogenesis imperfecta classification?","volume":"90","author":"Valadares","year":"2014","journal-title":"Jornal de Pediatria"},{"key":"10.1016\/j.bcp.2023.115584_b0770","unstructured":"Vall, H., & Parmar, M. (2022). Teriparatide. In StatPearls Publishing (Ed.), StatPearls. Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559248\/."},{"issue":"6","key":"10.1016\/j.bcp.2023.115584_b0775","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment","volume":"164","author":"Van Dijk","year":"2014","journal-title":"American Journal of Medical Genetics, Part A"},{"issue":"9","key":"10.1016\/j.bcp.2023.115584_b0780","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"issue":"October","key":"10.1016\/j.bcp.2023.115584_b0785","first-page":"1","article-title":"Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/j.bcp.2023.115584_b0790","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0795","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: A randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/j.bcp.2023.115584_b0800","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coms.2015.07.001","article-title":"Antiresorptive Therapies for Osteoporosis","volume":"27","author":"Weinerman","year":"2015","journal-title":"Oral and Maxillofacial Surgery Clinics of North America"},{"key":"10.1016\/j.bcp.2023.115584_b0805","doi-asserted-by":"crossref","unstructured":"Xie, J., Guo, J., Kanwal, Z., Wu, M., Lv, X., Ibrahim, N. A., Li, P., Buabeid, M. A., Arafa, E. S. A., & Sun, Q. (2020). Calcitonin and Bone Physiology: In Vitro, in Vivo, and Clinical Investigations. International Journal of Endocrinology, 2020. https:\/\/doi.org\/10.1155\/2020\/3236828.","DOI":"10.1155\/2020\/3236828"},{"issue":"1","key":"10.1016\/j.bcp.2023.115584_b0810","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cytogfr.2008.11.007","article-title":"NF-\u03baB modulators in osteolytic bone diseases","volume":"20","author":"Xu","year":"2009","journal-title":"Cytokine and Growth Factor Reviews"},{"key":"10.1016\/j.bcp.2023.115584_b0815","doi-asserted-by":"crossref","unstructured":"Xu, X. J., Lv, F., Liu, Y., Wang, J. Y., Ma, D. D., Asan, Wang, J. W., Song, L. J., Jiang, Y., Wang, O., Xia, W. B., Xing, X. P., & Li, M. (2017). Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid. Journal of Human Genetics, 62(2), 205\u2013211. https:\/\/doi.org\/10.1038\/jhg.2016.109.","DOI":"10.1038\/jhg.2016.109"},{"issue":"11","key":"10.1016\/j.bcp.2023.115584_b0820","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4158\/EP151184.OR","article-title":"The clinical characteristics and efficacy of bisphosphonates in audlt patients with osteogenesis impergecta","volume":"22","author":"Xu","year":"2016","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.bcp.2023.115584_b0825","doi-asserted-by":"crossref","unstructured":"Ying, Z. min, Hu, B., & Yan, S. gui. (2020). Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials. Orthopaedic Surgery, 12(4), 1293\u20131303. https:\/\/doi.org\/10.1111\/os.12611.","DOI":"10.1111\/os.12611"},{"issue":"2","key":"10.1016\/j.bcp.2023.115584_b0830","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/JPEM.2002.15.2.163","article-title":"Pamidronate treatment of osteogenesis imperfecta - Lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response","volume":"15","author":"Zacharin","year":"2002","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"11","key":"10.1016\/j.bcp.2023.115584_b0835","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1515\/JPEM.2004.17.11.1511","article-title":"Pamidronate treatment of less severe forms of osteogenesis imperfecta in children","volume":"17","author":"Zacharin","year":"2004","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"September","key":"10.1016\/j.bcp.2023.115584_b0840","first-page":"1","article-title":"Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study","volume":"13","author":"Zhang","year":"2022","journal-title":"Frontiers in Endocrinology"},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2023.115584_b0845","doi-asserted-by":"crossref","first-page":"341","DOI":"10.33549\/physiolres.933720","article-title":"New Molecules Modulating Bone Metabolism \u2013 New Perspectives in the Treatment of Osteoporosis","volume":"66","author":"Zofkova","year":"2017","journal-title":"Physiol. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223001752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223001752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:40:54Z","timestamp":1757770854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223001752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":168,"alternative-id":["S0006295223001752"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115584","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological options in the treatment of osteogenesis imperfecta: A comprehensive review of clinical and potential alternatives","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115584"}}